Fujirebio
Norwegian Startup Pre Diagnostics Developing Monocyte Test for Presymptomatic Alzheimer's Disease
Premium
The firm said its test detects biomarkers inside monocyte blood cells that reflect the reduced clearance of amyloid-beta plaque that leads to Alzheimer's disease.
Fujirebio Seeks to Expand Alzheimer's Test Portfolio With FDA Submission for β-Amyloid Ratio Assay
Premium
The firm said that a US FDA clearance would broaden the adoption of its growing portfolio of diagnostic assays for Alzheimer's disease.
Fujirebio Europe, Ohmx.bio Nab $873K Grant to Develop Clinical Third-Generation Sequencing Platform
The firms said that they will initially focus on the development of a portable, modular platform to detect highly polymorphic regions.
Fujirebio Diagnostics Applies for FDA 510(k) Clearance for Alzheimer's Disease Test
The firm said that its test uses cerebral spinal fluid to produce a numerical ratio of β-Amyloid1-42/ β-Amyloid1-40, and runs on its fully automated Lumipulse G1200 instrument system.
Centogene to Offer Fujirebio SARS-CoV-2 Antigen Test at German Airports
Centogene will install Fujirebio's Lumipulse G1200 instruments in its laboratories to analyze samples it collects from travelers using its oropharyngeal swabs.